<DOC>
	<DOCNO>NCT02581410</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety GSK Biologicals ' HZ/su vaccine adult ≥ 65 year age without Zostavax® vaccination least 5 year earlier .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster Subunit ( HZ/su ) Vaccine ( GSK1437173A ) Adults ≥ 65 Years Age With Without Zostavax® Vaccination Least 5 Years Earlier</brief_title>
	<detailed_description>The study evaluate two parallel group 200 adult ≥ 65 YOA ; one group ( Prev-Zvax ) previous Zostavax® vaccination least 5 year earlier , versus group without previous Zostavax® vaccination ( No prev-Zvax ) . The goal study generate immunogenicity , safety reactogenicity data respective vaccine .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female ≥ 65 year age time first vaccination . Written inform consent obtain subject prior perform study specific procedure . For No prevZvax group : • No previous vaccination Zostavax . For PrevZvax group : • Previous vaccination Zostavax ≥ 5 calendar year earlier . Documentation indicate date previous Zostavax vaccination require . Previous vaccination Zostavax &lt; 5 calendar year earlier and/or anyone ever receive single dose Zostavax . Previous vaccination VZV , administration HZ/su vaccine investigational nonregistered HZ vaccine ( except Zostavax PrevZvax group ) . Use investigational nonregistered product study vaccine period start 30 day first dose study vaccine , plan use study period . Chronic administration ( defined &gt; 14 consecutive day ) immunosuppressant immunemodifying drug period start 6 month prior first dose vaccine . ( For corticosteroid , prednisone dose &lt; 20 mg/day , equivalent , allow . ) Inhaled , topical intraarticular corticosteroid allow . Administration longacting immunemodifying drug ( e.g. , infliximab ) period start 6 month prior first vaccine dose expect administration time study period . Administration plan administration live vaccine period start 30 day first dose study vaccine end 30 day last dose study vaccine , , administration plan administration nonreplicating vaccine period start 8 day prior end 14 day either dose study vaccine . Current participation plan concurrent participation another clinical study , time study period , subject expose investigational noninvestigational product . Planned administration HZ vaccine ( include investigational nonregistered vaccine ) study vaccine entire study . History HZ suspect HZ screen visit Visit 1 . History reaction hypersensitivity likely exacerbate component vaccine/product . Any confirm suspected immunosuppressive immunodeficient condition result disease ( e.g. , malignancy , human immunodeficiency virus [ HIV ] infection ) immunosuppressive/cytotoxic therapy ( e.g. , medication use cancer chemotherapy , organ transplantation treat autoimmune disorder ) . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C ( 99.5°F ) oral route , axillary tympanic setting , ≥ 38.0°C/100.4°F rectal setting . The recommended route record temperature study oral . Subjects minor illness ( mild diarrhea , mild upper respiratory infection ) without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product period start 3 month precede first dose study vaccine plan administration study period . Significant underlying illness , opinion investigator , would expect prevent completion study . Any condition , opinion investigator , might interfere evaluation require study . Any condition , judgment investigator , would make intramuscular ( IM ) injection unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Zostavax®</keyword>
	<keyword>≥ 65 year age</keyword>
	<keyword>Herpes Zoster</keyword>
	<keyword>Shingles</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
</DOC>